Business
Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19
Database Lock Completed for Innovation Pharmaceuticals' Phase 2 Clinical Trial of Brilacidin for COVID-19.
About this update from Innovation Pharmaceuticals Inc.
[{"type":"text","content":"WAKEFIELD, MA / ACCESSWIRE / November 3, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical-stage biopharmaceutical company, today announced that the Company has received confirmation that hard lock of the database was completed for its Phase 2 clinical trial of Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Statistical analysis is underway, with topline results for the trial anticipated to be reported during the week of November 8, 2021.Alerts Sign-up for Innovation Pharmaceuticals email alerts is available at: http://www.ipharminc.com/email-alerts/About Innovation Pharmaceuticals Innovation Pharmaceuticals Inc. (IPIX) is a clinical-stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning future drug development plans, statements regarding the antiviral capabilities and therapeutic potential of Brilacidin and its impact on SARS-CoV-2 (COVID-19) and other viruses, as well as obtaining government regulatory approvals to commence clinical testing. Other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks but not limited to risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals for Brilacidin and Kevetrin in the US and other jurisdictions; that prior test results may not be replicated in future studies and trials, uncertainties and assumptions that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans,"...